,Question,Q_id,Company,Model,Answer,Rank,Score,Doc_index,Context_Answer
0,Does the company operate in countries out of the European Union?,1,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company operates in certain countries where the economic conditions continue to present significant challenges.,1,0.9892,1925,"In recent years, tax authorities around the world have increased their scrutiny of company tax filings, and have become more rigid in exercising any discretion they may have. The Company operates in certain countries where the economic conditions continue to present significant challenges. At the same time, the European Commission is finalizing its Anti Tax Avoidance Directive, which seeks to prevent tax avoidance by companies and to ensure that companies pay appropriate taxes in the markets where profits are effectively made and business is effectively performed."
1,Does the company operate in countries out of the European Union?,1,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.",2,0.0284,1560,"This leads to significant reductions in the emissions of key pollutant parameters (less than 10% of licensed amounts), e.g. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. Additionally this technology offers the potential to reduce discharges of residual APIs to the environment."
2,Does the company operate in countries out of the European Union?,1,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Like other companies in the healthcare industry, the Company is subject to extensive regulation, investigations and legal action, by national, state and local government agencies in the U.S. and other countries in which they operate.",3,0.0032,1639,"Defaults, Dividend Arrearages and Delinquencies ..........................................................................................................219 Item 14. Like other companies in the healthcare industry, the Company is subject to extensive regulation, investigations and legal action, by national, state and local government agencies in the U.S. and other countries in which they operate. Principal Accountant Fees and Services ..............................................................................................................................224 Item 16D."
3,Does the company operate in countries out of the European Union?,1,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company faces substantial competition in all three operating segments and in all geographic markets.,4,0.0015,1620,W6.2a 	(W6.2a) Identify the position(s) of the individual(s) on the board with responsibility for water-related issues. The Company faces substantial competition in all three operating segments and in all geographic markets. Name of the position(s) and/or committee(s) 	Responsibility 	Frequency of reporting to the board on water-related issues 	Please explain 	Name of the position(s) and/or committee(s) 	Responsibility 	Frequency of reporting to the board on water-related issues 	Please explain 	W6.5 	(W6.5) Do you engage in activities that could either directly or indirectly influence public policy on water through any of the following?
4,Does the company operate in countries out of the European Union?,1,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Johnson & Johnson is a holding company, which has more than 260 operating companies conducting business in virtually all countries of the world.",5,0.0012,1521,"The Novartis Global Health and Corporate Responsibility Leadership Team (GH CRLT) comprised of leaders from each division and across multiple functions of the company, guides this work. Johnson & Johnson is a holding company, which has more than 260 operating companies conducting business in virtually all countries of the world. For external advocacy, Corporate Affairs has developed a document describing eight advocacy principles as guidance for efforts regarding CR."
5,Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries,2,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Following FDA inspections in 2015, McNEIL-PPC received notifications from the FDA that all three manufacturing facilities are in conformity with applicable laws and regulations, and commercial production has restarted.",1,0.0017,1686,"Because we typically have substantially reduced marketing and research and development expenses related to products that are in their final years of exclusivity, the initial loss of intellectual property protection for a product during the year could also have an impact on our 2019 operating income in an amount corresponding to a significant portion of the product’s lost sales. Following FDA inspections in 2015, McNEIL-PPC received notifications from the FDA that all three manufacturing facilities are in conformity with applicable laws and regulations, and commercial production has restarted. Key Information 12pharmaceutical products in such geographies; and our ability to successfully develop and launch profitable new products to replace the income lost to generic competition."
6,Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries,2,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Regulatory issues regarding compliance with Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation.",2,0.0007,1640,"Material Modifications to the Rights of Security Holders and Use of Proceeds .............................................220 Item 15. Regulatory issues regarding compliance with Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. Exemptions from the Listing Standards for Audit Committees ................................................................................225 Item 16E."
7,Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries,2,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,These trademarks are protected by registration in the U.S. and other countries where such products are marketed.,3,0.0007,1549,"Linkages and trade-offs W9.1 (W9.1) Has your organization identified any linkages or tradeoffs between water and other environmental issues in its direct operations and/or other parts of its value chain? These trademarks are protected by registration in the U.S. and other countries where such products are marketed. Several Novartis sites in Austria, Italy, Spain and Slovenia use large quantities of water from river side banks to cool their production processes and additional sites in e.g."
8,Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries,2,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.",4,0.0006,1591,"Impact of the engagement and measures of success 	Comment 	W1.4c 	(W1.4c) What is your organization’s rationale and strategy for prioritizing engagements with customers or other partners in its value chain? Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution. W3.3a 	(W3.3a) Select the options that best describe your procedures for identifying and assessing water-related risks."
9,Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries,2,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,Illegal Importation of Pharmaceutical Products: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company’s sales and profitability in the U.S. and other countries in which the Company operates.,5,0.0006,1653,"Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Illegal Importation of Pharmaceutical Products: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company’s sales and profitability in the U.S. and other countries in which the Company operates. Operating and Financial Review and Prospects.” Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Annual Report as anticipated, believed, estimated or expected."
10,"Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?",3,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities.",1,0.0098,1894,"We may particularly rely on third parties in developing countries, including for the sales, marketing and distribution of our products, and to obtain the intermediate and raw materials used in the manufacture of our products. In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities. In addition, governments and the public are increasingly placing pressure on major corporations, including Novartis, to take responsibility for compliance with human rights and appropriate environmental practices, as well as other actions, of their third-party contractors around the world."
11,"Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?",3,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution.",2,0.0075,1645,"Operating and Financial Review and Prospects,” together with the sections on products in development and key development projects of our businesses (see “Item 4. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Unless the context requires otherwise, the words “we,” “our,” “us,” “Novartis,” “Group,” “Company,” and similar words or phrases in this Annual Report refer to Novartis AG and its consolidated affiliates."
12,"Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?",3,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company’s business is heavily regulated and therefore involves significant interaction with foreign officials.,3,0.0068,1658,"Financial Statements” in this Form 20-F. All financial data should be read in conjunction with “Item 5. The Company’s business is heavily regulated and therefore involves significant interaction with foreign officials. In addition, a combined consumer healthcare business was created through the combination of the Novartis OTC and GlaxoSmithKline (GSK) Consumer Healthcare businesses."
13,"Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?",3,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In all of their product lines, the Company’s subsidiaries compete with companies both locally and globally.",4,0.0046,1553,"At these sites the quantity and temperature of the water is important for the efficiency of cooling rather than the water quality. In all of their product lines, the Company’s subsidiaries compete with companies both locally and globally. We estimated that energy and related GHG emissions would increase be 20-30% at these sites, if water was not available anymore for cooling."
14,"Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?",3,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In all of its product lines, the Company competes with companies both locally and globally, throughout the world.",5,0.0042,1557,"With this approach to use water for cooling instead of electricity, these sites effectively contribute to the Novartis energy efficiency program and to the related GHG targets. In all of its product lines, the Company competes with companies both locally and globally, throughout the world. Increased energy efficiency Description of linkage/tradeoff Currently 2 sites have installed wastewater treatment technology based on fine-bubble diffused aeration."
15,Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?,4,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Our Company has comprehensive policies, procedures and required training that help employees comply with laws and regulations.",1,0.0446,2696,"If we or our third-party suppliers fail to comply fully with regulations, then there could be a product recall or other shutdown or disruption of our production activities. Our Company has comprehensive policies, procedures and required training that help employees comply with laws and regulations. We have implemented a global manufacturing strategy to maximize business continuity in case of such events."
16,Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?,4,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"While we aim to achieve outcomes in all of the Company’s s work, the identified targets for the SDG commitment are reflective of the Company’s reach — individuals whose lives may benefit from our combined efforts with our partners.",2,0.0252,124,"While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. While we aim to achieve outcomes in all of the Company’s s work, the identified targets for the SDG commitment are reflective of the Company’s reach — individuals whose lives may benefit from our combined efforts with our partners. Direct operations Risk type Transition risk Primary climate-related risk driver Policy and legal: Enhanced emissions-reporting obligations Type of financial impact driver Policy and legal: Increased operating costs (e.g., higher compliance costs, increased insurance premiums) Company- specific descriptio."
17,Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?,4,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations.,3,0.0185,1746,"We could be impacted by new laws and regulations, and by failures to comply with law, legal proceedings and government investigations. The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations. Such legal requirements can vary from country to country, and new requirements may be imposed on us from time to time as a result of changing government and public expectations regarding the healthcare industry, and acceptable corporate behavior generally."
18,Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?,4,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In response to these concerns, the Company has a long-standing policy of pricing products responsibly.",4,0.0046,1924,"However, mechanisms developed to resolve such conflicting claims are largely untried, and can be expected to be very lengthy. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. As part of this, the Organization for Economic Co-operation and Development (OECD) has proposed a number of tax law changes under its Base Erosion and Profit Shifting (BEPS) Action Plans to address issues of transparency, coherence and substance."
19,Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?,4,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"We have processes, guidance and procedures in place to help you follow this Code, Company policy and the law.",5,0.0041,2681,"These lenses offer clear, seamless vision at all distances and combine the innovative Air Optix multifocal design with lasting lens surface moisture provided by the HydraGlyde moisture matrix. We have processes, guidance and procedures in place to help you follow this Code, Company policy and the law. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery."
20,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?,5,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,Ensuring Business Continuity:Our businesses are required to maintain a strong business continuity management program with centralized coordination and crisis management for regional events.,1,0.8492,584,Carbon pricing 	C11.1 	(C11.1) Are any of your operations or activities regulated by a carbon pricing system (i.e. Ensuring Business Continuity:Our businesses are required to maintain a strong business continuity management program with centralized coordination and crisis management for regional events. Allowances purchased 	Verified emissions in metric tons CO2e 	Details of ownership 	Comment 	C11.1d 	(C11.1d) What is your strategy for complying with the systems in which you participate or anticipate participating?
21,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?,5,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.",2,0.1254,1662,"2 Cash dividends represent cash payments in the applicable year that generally relates to earnings of the previous year. Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation. 4 Personnel cost include wages, salaries, allowances, commissions and bonuses to staff, overtime, awards, holiday pay, severance payments and social welfare expenses."
22,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?,5,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.",3,0.0143,1932,"Switzerland is in the process of considering the implementation of corporate tax reform, which could become effective as early as the first quarter of 2019. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. There is also a risk that the EU may not be satisfied with the outcome of Switzerland’s tax reform efforts, and take steps to seek further changes."
23,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?,5,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company’s third party providers have required capabilities and controls, to address this risk.",4,0.0075,1925,"In recent years, tax authorities around the world have increased their scrutiny of company tax filings, and have become more rigid in exercising any discretion they may have. The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company’s third party providers have required capabilities and controls, to address this risk. At the same time, the European Commission is finalizing its Anti Tax Avoidance Directive, which seeks to prevent tax avoidance by companies and to ensure that companies pay appropriate taxes in the markets where profits are effectively made and business is effectively performed."
24,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?,5,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,These rights are essential to the Company’s businesses and materially important to the Company’s results of operations.,5,0.0067,1608,Explanation of financial impact 	Type of opportunity 	Primary water-related opportunity 	Company-specific description & strategy to realize opportunity 	Estimated timeframe for realization 	Magnitude of potential financial impact 	Potential financial impact. These rights are essential to the Company’s businesses and materially important to the Company’s results of operations. Explanation of financial impact 	Type of opportunity 	Primary water-related opportunity 	Company-specific description & strategy to realize opportunity 	Estimated timeframe for realization 	Magnitude of potential financial impact 	Potential financial impact.
25,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?,6,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control.,1,0.0843,1740,"The growth of overall healthcare costs as a percentage of gross domestic product in many countries means that governments and payers are under intense pressure to control healthcare spending even more tightly than in the past. The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control. These pressures are further compounded by significant controversies and intense political debate and publicity about prices for pharmaceuticals that some consider excessive, including government regulatory efforts, funding restrictions, legislative proposals, policy interpretations, investigations and legal proceedings regarding pharmaceutical pricing practices."
26,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?,6,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.",2,0.01,1932,"Switzerland is in the process of considering the implementation of corporate tax reform, which could become effective as early as the first quarter of 2019. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. There is also a risk that the EU may not be satisfied with the outcome of Switzerland’s tax reform efforts, and take steps to seek further changes."
27,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?,6,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In addition, the Company’s Law Department provides direct guidance and training on the Company’s policies.",3,0.0045,1750,"These laws and regulations include requirements that we disclose payments or other transfers of value made to healthcare professionals and organizations, as well as information relating to the prices for our products. In addition, the Company’s Law Department provides direct guidance and training on the Company’s policies. In addition, companies and executives in our industry continue to face significant government investigations, legal proceedings and law enforcement activities, both in the US and in countries around the world."
28,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?,6,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.",4,0.0027,1874,"Sudden increases in economic, currency or financial market volatility in different countries have also impacted, and may continue to unpredictably impact, our business or results of operations, including the conversion of our operating results into our reporting currency, the US dollar, as well as the value of our investments in our pension plans. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. See also “—Our business is affected by pressures on pricing and reimbursement for our products,” above, and “Item 5."
29,Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?,6,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company is negotiating settlements of these cases and the related costs are reflected in the Company’s accruals.,5,0.0015,1608,Explanation of financial impact 	Type of opportunity 	Primary water-related opportunity 	Company-specific description & strategy to realize opportunity 	Estimated timeframe for realization 	Magnitude of potential financial impact 	Potential financial impact. The Company is negotiating settlements of these cases and the related costs are reflected in the Company’s accruals. Explanation of financial impact 	Type of opportunity 	Primary water-related opportunity 	Company-specific description & strategy to realize opportunity 	Estimated timeframe for realization 	Magnitude of potential financial impact 	Potential financial impact.
30,Has the company formalized  a strategy to reduce its greenhouse gas  emissions?,7,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"We have a long history of innovation and leadership in energy management, and have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions.",1,0.0349,1164,"This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We have a long history of innovation and leadership in energy management, and have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions. Example: raw material, subcontracted manufacturing services, packaging 2 All suppliers necessary to run an organization, such as utilities, IT hardware/software, furniture, capital expenditure, marketing supplies, etc."
31,Has the company formalized  a strategy to reduce its greenhouse gas  emissions?,7,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"For example, through our Sustainable Procurement Program, we encourage our suppliers to set, and to report on, the progress of public environmental goals, including targets related to energy use and carbon emissions reduction.",2,0.0037,1184,"We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our assurance conclusions. For example, through our Sustainable Procurement Program, we encourage our suppliers to set, and to report on, the progress of public environmental goals, including targets related to energy use and carbon emissions reduction. We provide healthcare solutions that address the evolving needs of patients and societies worldwide."
32,Has the company formalized  a strategy to reduce its greenhouse gas  emissions?,7,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,• Further enhance supplier engagement programs to encourage suppliers to reduce their GHG emissions associated with our purchased goods and services.,3,0.003,1154,"Examples may include responding to the needs of low-income patients and to the growing healthcare burden of noncommunicable diseases (NCDs). • Further enhance supplier engagement programs to encourage suppliers to reduce their GHG emissions associated with our purchased goods and services. Examples may include using big data analysis or developing personalized healthcare solutions (e.g., products with companion diagnostic tests), and improving health solutions based on data collected by wearables."
33,Has the company formalized  a strategy to reduce its greenhouse gas  emissions?,7,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,World Business Council for Sustainable Development (WBCSD)/World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol for Greenhouse Gas emissions.,4,0.0029,1283,"In 2018 we focus on the water data, used more “meaningful” questions and aligned them with the KPIs we intend to use as an indicator of the environmental water performance of our suppliers. World Business Council for Sustainable Development (WBCSD)/World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol for Greenhouse Gas emissions. Impact of the engagement and measures of success Novartis is engaging with its suppliers through capability building webinars such as the CDP Supply Chain lead member service."
34,Has the company formalized  a strategy to reduce its greenhouse gas  emissions?,7,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Johnson & Johnson participates in the U.S. EPA's SmartWay program, which helps companies voluntarily increase transportation energy efficiency while decreasing GHG emissions and air pollution.",5,0.0022,1186,"We provide healthcare solutions that address the evolving needs of patients and societies worldwide. Johnson & Johnson participates in the U.S. EPA's SmartWay program, which helps companies voluntarily increase transportation energy efficiency while decreasing GHG emissions and air pollution. Rapidly aging populations and the growth in chronic illnesses such as heart disease and cancer continue to increase demand for care and put pressure on health systems around the world."
35,"Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?",8,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,We focus our energy and carbon efficiency work on three main areas: reducing energy demand and maximizing energy efficiency in our operations; shifting to low-carbon and renewable energy sources to meet the remaining demand; and improving our influence over emissions in our value chain.,1,0.9082,1165,"We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice. We focus our energy and carbon efficiency work on three main areas: reducing energy demand and maximizing energy efficiency in our operations; shifting to low-carbon and renewable energy sources to meet the remaining demand; and improving our influence over emissions in our value chain. 3 Suppliers with whom we have a direct contractual relationship pertaining to the delivery of goods and services 4 The sum of individual country totals is larger than the grand total because one supplier can serve multiple countries."
36,"Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?",8,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"We have a long history of innovation and leadership in energy management, and have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions.",2,0.0728,1164,"This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We have a long history of innovation and leadership in energy management, and have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions. Example: raw material, subcontracted manufacturing services, packaging 2 All suppliers necessary to run an organization, such as utilities, IT hardware/software, furniture, capital expenditure, marketing supplies, etc."
37,"Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?",8,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Johnson & Johnson participates in the U.S. EPA's SmartWay program, which helps companies voluntarily increase transportation energy efficiency while decreasing GHG emissions and air pollution.",3,0.019,1186,"We provide healthcare solutions that address the evolving needs of patients and societies worldwide. Johnson & Johnson participates in the U.S. EPA's SmartWay program, which helps companies voluntarily increase transportation energy efficiency while decreasing GHG emissions and air pollution. Rapidly aging populations and the growth in chronic illnesses such as heart disease and cancer continue to increase demand for care and put pressure on health systems around the world."
38,"Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?",8,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.",4,0.0184,1638,"Quantitative and Qualitative Disclosures About Market Risk ....................................................................................216 Item 12. The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties. Material Modifications to the Rights of Security Holders and Use of Proceeds .............................................220 Item 15."
39,"Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?",8,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control.,5,0.0156,1573,W-FI (W-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control. This is confidential SW1.2 (SW1.2) Are you able to provide geolocation data for your site facilities not already reported in W5.1?
40,Does the company monitor performance indicators to assess its progress compared to its climate related commitments?,9,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In addition to this Report, we disclose our performance against these public commitments in the CDP Climate Change Report.",1,0.8862,1166,"Example: raw material, subcontracted manufacturing services, packaging 2 All suppliers necessary to run an organization, such as utilities, IT hardware/software, furniture, capital expenditure, marketing supplies, etc. In addition to this Report, we disclose our performance against these public commitments in the CDP Climate Change Report. Suppliers are counted for each country they serve, but they are counted only once for the grand total."
41,Does the company monitor performance indicators to assess its progress compared to its climate related commitments?,9,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company’s businesses and planning and forecasting for future periods.",2,0.0245,2635,"For generic applicants who are the first to file their ANDA containing a certification claiming non-infringement or patent invalidity, the Hatch-Waxman Act provides those applicants with Item 4. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company’s businesses and planning and forecasting for future periods. However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant."
42,Does the company monitor performance indicators to assess its progress compared to its climate related commitments?,9,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Management uses these measures internally for planning, forecasting and evaluating the performances of the Company’s businesses, including allocating resources and evaluating results relative to employee performance compensation targets.",3,0.0178,2627,"In 2018, the divestment of the Boucherville, Canada, development (and associated manufacturing) facility to Avara Pharmaceutical Services was announced and subsequently completed, including a long-term agreement to secure supply of key products to the Canadian market. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company’s businesses, including allocating resources and evaluating results relative to employee performance compensation targets. The Hatch-Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown in bioequivalence studies to be of identical quality and purity, and to be therapeutically equivalent to the reference product."
43,Does the company monitor performance indicators to assess its progress compared to its climate related commitments?,9,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,• Earned a place on CDP’s Climate Change A List among companies demonstrating global leadership on corporate climate action.,4,0.0094,1150,"Systems to ensure that the personally identifiable information of patients, employees, consumers and others is responsibly and securely collected, transferred and stored. • Earned a place on CDP’s Climate Change A List among companies demonstrating global leadership on corporate climate action. This includes the research of new compounds but also the modification of existing medicines (i.e., to improve access or efficacy for poor and specifically vulnerable patient groups)."
44,Does the company monitor performance indicators to assess its progress compared to its climate related commitments?,9,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"While we aim to achieve outcomes in all of the Company’s s work, the identified targets for the SDG commitment are reflective of the Company’s reach — individuals whose lives may benefit from our combined efforts with our partners.",5,0.0072,124,"While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. While we aim to achieve outcomes in all of the Company’s s work, the identified targets for the SDG commitment are reflective of the Company’s reach — individuals whose lives may benefit from our combined efforts with our partners. Direct operations Risk type Transition risk Primary climate-related risk driver Policy and legal: Enhanced emissions-reporting obligations Type of financial impact driver Policy and legal: Increased operating costs (e.g., higher compliance costs, increased insurance premiums) Company- specific descriptio."
45,Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?,10,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control.,1,0.0024,1553,"At these sites the quantity and temperature of the water is important for the efficiency of cooling rather than the water quality. The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company’s control. We estimated that energy and related GHG emissions would increase be 20-30% at these sites, if water was not available anymore for cooling."
46,Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?,10,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company is cooperating with these government inquiries and will be producing documents in response.,2,0.0014,2386,"In June 2016, we announced a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The Company is cooperating with these government inquiries and will be producing documents in response. The original terms also included co-development of Xencor’s bispecific T-cell-engaging antibody targeting CD3xCD20 for the treatment of B-cell malignancies, which we have since agreed to revert to Xencor."
47,Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?,10,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.",3,0.0012,1932,"Switzerland is in the process of considering the implementation of corporate tax reform, which could become effective as early as the first quarter of 2019. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. There is also a risk that the EU may not be satisfied with the outcome of Switzerland’s tax reform efforts, and take steps to seek further changes."
48,Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?,10,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company’s results of operations without including all events during a period and may not provide a comparable view of the Company’s performance to that of other companies in the health care industry.,4,0.0011,2764,"In 2012, Novartis announced the construction of a new state-of-the-art production facility to produce solid dosage form medicines for the Innovative Medicines Division in Stein, Switzerland. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company’s results of operations without including all events during a period and may not provide a comparable view of the Company’s performance to that of other companies in the health care industry. In 2012, we announced the planned construction of a new state-of-the-art biotechnology production site in Singapore, with a planned investment of over USD 0.8 bil-lion."
49,Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?,10,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition.,5,0.0009,908,"Further, in 2018, the WHO issued a rapid communication with revised guidance on tuberculosis, specifically on the longer regimen to treat multidrug- and rifampicin-resistant tuberculosis, prioritizing oral agents over injectables. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition. Novartis is continuing its partnership with the WHO to provide clofazimine, as part of a multidrug therapy, free of charge for leprosy patients in various lower-income countries."
50,Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?,11,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Management uses these measures internally for planning, forecasting and evaluating the performances of the Company’s businesses, including allocating resources and evaluating results relative to employee performance compensation targets.",1,0.0772,2627,"In 2018, the divestment of the Boucherville, Canada, development (and associated manufacturing) facility to Avara Pharmaceutical Services was announced and subsequently completed, including a long-term agreement to secure supply of key products to the Canadian market. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company’s businesses, including allocating resources and evaluating results relative to employee performance compensation targets. The Hatch-Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown in bioequivalence studies to be of identical quality and purity, and to be therapeutically equivalent to the reference product."
51,Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?,11,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company’s businesses and planning and forecasting for future periods.",2,0.0483,2635,"For generic applicants who are the first to file their ANDA containing a certification claiming non-infringement or patent invalidity, the Hatch-Waxman Act provides those applicants with Item 4. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company’s businesses and planning and forecasting for future periods. However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant."
52,Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?,11,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"For example, through our Sustainable Procurement Program, we encourage our suppliers to set, and to report on, the progress of public environmental goals, including targets related to energy use and carbon emissions reduction.",3,0.011,2264,"Kisqali was developed by Novartis as part of a drug discovery collaboration with Astex Pharmaceuticals. For example, through our Sustainable Procurement Program, we encourage our suppliers to set, and to report on, the progress of public environmental goals, including targets related to energy use and carbon emissions reduction. Novartis is starting pivotal clinical studies of Kymriah in relapsed or refractory (r/r) follicular lymphoma, adult r/r acute lymphoblastic leukemia (ALL), first-line high-risk pediatric ALL, diffuse large B-cell lymphoma after first relapse, and r/r chronic lymphoblastic leukemia."
53,Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?,11,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,Emissions were calculated using company spend in the reporting year paired with appropriate economic input/output (IO) emission factors from Carnegie Melon’s 2002 dataset.,4,0.0051,1198,"It also drives the adoption of common standards and procedures, best practices and new technologies, with the aim of greater efficiency and effectiveness. Emissions were calculated using company spend in the reporting year paired with appropriate economic input/output (IO) emission factors from Carnegie Melon’s 2002 dataset. Sandoz offers patients and healthcare professionals' high quality, affordable generics and biosimilars."
54,Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?,11,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company’s results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company’s performance to other companies in the health care industry.",5,0.0026,2629,"The Hatch-Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown in bioequivalence studies to be of identical quality and purity, and to be therapeutically equivalent to the reference product. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company’s results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company’s performance to other companies in the health care industry. However, delays can occur if issues arise regarding the interpretation of bioequivalence study data, labeling requirements for the generic product, or qualifying the supply of active ingredients."
55,"Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)",12,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Our Company has comprehensive policies, procedures and required training that help employees comply with laws and regulations.",1,0.1682,2696,"If we or our third-party suppliers fail to comply fully with regulations, then there could be a product recall or other shutdown or disruption of our production activities. Our Company has comprehensive policies, procedures and required training that help employees comply with laws and regulations. We have implemented a global manufacturing strategy to maximize business continuity in case of such events."
56,"Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)",12,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In addition, the Company’s Law Department provides direct guidance and training on the Company’s policies.",2,0.0319,908,"Further, in 2018, the WHO issued a rapid communication with revised guidance on tuberculosis, specifically on the longer regimen to treat multidrug- and rifampicin-resistant tuberculosis, prioritizing oral agents over injectables. In addition, the Company’s Law Department provides direct guidance and training on the Company’s policies. Novartis is continuing its partnership with the WHO to provide clofazimine, as part of a multidrug therapy, free of charge for leprosy patients in various lower-income countries."
57,"Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)",12,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"We have processes, guidance and procedures in place to help you follow this Code, Company policy and the law.",3,0.0192,2681,"These lenses offer clear, seamless vision at all distances and combine the innovative Air Optix multifocal design with lasting lens surface moisture provided by the HydraGlyde moisture matrix. We have processes, guidance and procedures in place to help you follow this Code, Company policy and the law. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery."
58,"Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)",12,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Whenever we become aware of a violation of the Code, Company policy or the law, we will act to address the problem and prevent future occurrences.",4,0.0074,2670,"For glaucoma surgery, Alcon offers the EX-PRESS glaucoma filtration device, and formerly distributed the CyPass Micro-Stent. Whenever we become aware of a violation of the Code, Company policy or the law, we will act to address the problem and prevent future occurrences. In addition, Alcon provides advanced viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery."
59,"Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)",12,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"In response to these concerns, the Company has a long-standing policy of pricing products responsibly.",5,0.0065,1924,"However, mechanisms developed to resolve such conflicting claims are largely untried, and can be expected to be very lengthy. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. As part of this, the Organization for Economic Co-operation and Development (OECD) has proposed a number of tax law changes under its Base Erosion and Profit Shifting (BEPS) Action Plans to address issues of transparency, coherence and substance."
60,Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?,13,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company’s results of operations without including all events during a period and may not provide a comparable view of the Company’s performance to that of other companies in the health care industry.,1,0.0382,2636,"Information on the Company 68 180 days of marketing exclusivity to recoup the expense of challenging the patents on the reference product. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company’s results of operations without including all events during a period and may not provide a comparable view of the Company’s performance to that of other companies in the health care industry. In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure."
61,Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?,13,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care.",2,0.0032,1923,"The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care. In recent years, tax authorities around the world have increased their scrutiny of company tax filings, and have become more rigid in exercising any discretion they may have."
62,Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?,13,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.",3,0.0014,1932,"Switzerland is in the process of considering the implementation of corporate tax reform, which could become effective as early as the first quarter of 2019. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. There is also a risk that the EU may not be satisfied with the outcome of Switzerland’s tax reform efforts, and take steps to seek further changes."
63,Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?,13,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,See Note 10 to the Consolidated Financial Statements for further details on these rates and the effect a rate change to the health care cost trend would have on the Company’s results of operations.,4,0.0014,1915,"For these defined benefits plans, we are required to make significant assumptions and estimates about future events in calculating the present value of expected future plan expenses and liabilities. See Note 10 to the Consolidated Financial Statements for further details on these rates and the effect a rate change to the health care cost trend would have on the Company’s results of operations. Either such event could have a material effect on our results of operations and financial condition."
64,Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?,13,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.",5,0.0013,2114,"For instance, in the last two years, we have seen a positive trend in generally effective internal compliance audits. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. However, the proportion of substantiated allegations related to ethics and compliance matters remains stable."
65,Is there a crisis management scheme to cope with an identified issue on product safety?,14,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,A: Safety procedures are in place to keep you safe and to protect the integrity of our products and the health of those who use them.,1,0.0158,2759,"• In April 2018, we announced the planned closure of our Kaminoyama, Japan, site and the transfer of all packaging activities to Sasayama, Japan, by 2020. A: Safety procedures are in place to keep you safe and to protect the integrity of our products and the health of those who use them. • In September 2018, we announced the acquisition of our Mahad, India, site by Olon S.p.A., which we expect to be completed in 2019."
66,Is there a crisis management scheme to cope with an identified issue on product safety?,14,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"We firmly believe that identifying and understanding environmental, safety and employee issues, including potential human rights concerns, are critical components of our acquisition and other business development activities.",2,0.0044,1006,"The results showed that employees overwhelmingly enjoy coming to work and are proud of the company, but they also revealed concerns about competitive behaviors and the desire for a more collaborative style of working. We firmly believe that identifying and understanding environmental, safety and employee issues, including potential human rights concerns, are critical components of our acquisition and other business development activities. These expectations are reflected in a new 360-degree assessment that forms the foundation for leadership development in the company, and are now embedded in our immersive development programs."
67,Is there a crisis management scheme to cope with an identified issue on product safety?,14,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Many of our brands and products have been trusted by consumers for products have been trusted by consumers for products have been trusted by consumers for decades, and when the safety of our productsdecades, and when the safety of our productsdecades, and when the safety of our products is challenged, we will continue to defend them.is challenged, we will continue to defend them.is challenged, we will continue to defend them.",3,0.0022,1468,"At our technical operation site in Cork, Ireland, purified water, which was primarily used to rinse products, is recycled for sanitary purposes, like the flushing of toilets. Many of our brands and products have been trusted by consumers for products have been trusted by consumers for products have been trusted by consumers for decades, and when the safety of our productsdecades, and when the safety of our productsdecades, and when the safety of our products is challenged, we will continue to defend them.is challenged, we will continue to defend them.is challenged, we will continue to defend them. Estimated timeframe for realization Current - up to 1 year Magnitude of potential financial impact Low Potential financial impact 15000."
68,Is there a crisis management scheme to cope with an identified issue on product safety?,14,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,"Day-to-day safety decisions are made by multi-disciplinary Safety management teams, and more complex decisions are managed by segment Medical Safety Councils, which are chaired by the Chief Medical Officer responsible for each sector.",4,0.0016,821,"In addition, to harmonize the patient reach calculation methodology across Novartis, the malaria patient reach calculation was revised. Day-to-day safety decisions are made by multi-disciplinary Safety management teams, and more complex decisions are managed by segment Medical Safety Councils, which are chaired by the Chief Medical Officer responsible for each sector. This seems to be partly because the poorest people are located on “medicine islands,” where a lack of local competition leads to higher prices, and traveling to outlets where prices are lower is difficult."
69,Is there a crisis management scheme to cope with an identified issue on product safety?,14,Johnson,Tf_Idf_Cluster_Bert_Finetuned_MsMarco,The FDA is currently exploring further research to enable increasingly proactive safety surveillance.,5,0.0011,837,"In the field of clinical trials, we are working to expand the capacity of sites for global trials of our novel antimalarial agents, in partnership with Medicines for Malaria Venture and the Wellcome Trust. The FDA is currently exploring further research to enable increasingly proactive safety surveillance. inspiring the neXt generation of sCientists Most medical research is currently conducted in developed countries, yet most of the world’s population lives in the developing world."
